Developing clinical assays to routinely screen patients for neutralizing antibodies is difficult and likely not cost-effective.

“it's quite a difficult to say that requires and you're incubating the patient's plasma or serum with the actual virus then plating it out over cells and then watching the virus infect the cells over the next 2 3 4 5 6 days depending on the virus so what you're looking for is a serum that will block the virus of interest from infecting the sounds so it's not trivial but we standardly do it for HIV for Zika for dengue in a laboratory and we'll soon be doing it for the new corona virus”